Crossmark

A platform approach as a plausible option for nonclinical safety assessment of adjuvanted vaccines

Published Online: 2025-08-13

Authors

Destexhe, Eric
License Information

Text and Data Mining valid from 2025-08-13

Version of Record valid from 2025-08-13
More Information

Article History

Received: 4 April 2025

Accepted: 25 July 2025

First Online: 13 August 2025

Competing interests

: E.D. is an employee of the GSK group of companies and holds stock in GSK.

Document is current